Providing Consultative DMPK Solutions Bridging Drug Discovery and Development

Providing Consultative DMPK Solutions Bridging Drug Discovery and Development

Aired:  11/21/2013 2:00:00 AM

XenoTech and XenoGesis work together to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early stage drug discovery through development and beyond. Our partnership was developed to help mitigate the risk and cost associated with clinical failure. Efficacy and safety are now the leading causes of attrition and are linked to drug exposure in target and off-target tissues. While pharmacokinetics is no longer the leading cause of failure, a drug’s exposure is driven by its pharmacokinetic properties and ultimately remains critical for successful pharmacodynamics and safety. We will showcase the consultative basis of our DMPK CRO alliance and highlight our capabilities with real-life examples of our unique combination of expertise.

Key concepts discussed in this webinar will include:

  • Factors that may contribute to low quality leads and ways to overcome these problems
  • Case studies to illustrate how the XenoTech / XenoGesis alliance can positively impact drug development
  • Capabilities and expertise of each CRO

Give Feedback